U
Ukko
Improving the lives of millions that suffer from food allergies and disorders using immunology, computational biology, and plant science
About Ukko
Ukko is a pioneering company focused on addressing food allergies and sensitivities, particularly gluten-related disorders. The company operates in the biotechnology and healthcare markets, leveraging cutting-edge technologies in immunology, computational biology, and protein engineering. Ukko's core business involves mapping the molecular structure of food allergies and disorders to understand the biological mechanisms driving human food interactions. This comprehensive, clinically validated map enables Ukko to design proteins that do not trigger immune responses, which are then applied to both food and therapeutic markets.
Read full description
Ukko serves a diverse range of clients, including individuals suffering from food allergies and gluten-related disorders, healthcare providers, and food manufacturers. The company’s business model is centered around the development and commercialization of these specialized proteins. Revenue is generated through the sale of these proteins to food manufacturers and healthcare providers, as well as through partnerships and licensing agreements.
Ukko's innovative approach aims to reduce the significant social, health, and economic impacts associated with food allergies and gluten disorders, which are on the rise globally.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Rehovot, Israel
- Employees
- 58
- Open positions
- None listed
- Dealroom signal
- 80.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Innovative Food
- Sector
- Biotech & Life Sciences, Biotechnology, Allergy, Plant-Based, Alternative Protein, Sustainable Development Goals, Macro-Nutrients, Liver, Biotech and Pharma
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Ukko.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2024 | $8.3M | $200M | Undisclosed | — |
| LATE VCOther financing | Jun 2022 | $4M | $200M | Undisclosed | — |
Growth signals
Latest recorded traffic for Ukko is 1.2K monthly website visits, up 0% over the last three months. Ukko's team grew 7.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Khosla Ventures
Slow Ventures
Innovation Endeavors
Marc Benioff- IAIzhar Armony
Leaps by Bayer
Skyviews Life Science
Fall Line Capital
Continental Grain
PeakBridge
Time Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ukko on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ukko’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.